当前位置:首页 / 大柴胡汤加味方治疗高脂血症(痰瘀内阻证)的临床研究
| 更新时间:2026-11-20
|
大柴胡汤加味方治疗高脂血症(痰瘀内阻证)的临床研究
Clinical study on modified Da Chaihu Tang in the treatment of hyperlipidemia (syndrome of phlegm and blood stasis obstructing the interior)

内科 页码:611-616

作者机构:1 天津市河东区大直沽街社区卫生服务中心中医科,天津市 300170;2 中国人民武装警察部队特色医学中心研究部,天津市 300162;3 天津康汇医院医学检验科,天津市 300385

DOI:10.16121/j.cnki.cn45-1347/r.2026.05.15

  • 中文简介
  • 英文简介
  • 参考文献

目的 探讨大柴胡汤加味方治疗高脂血症(痰瘀内阻证)的临床效果及安全性。方法 选取2023年2月至2024年10月于天津市河东区大直沽街社区卫生服务中心就诊的102例高脂血症(痰瘀内阻证)患者作为研究对象,采用随机数字表法将其分为观察组与对照组,每组51例。两组均接受生活方式干预;同时,对照组接受口服辛伐他汀治疗(1次/d,20 mg/次),观察组接受大柴胡汤加味方治疗(每日1剂,分2次口服)。两组均连续治疗8周。比较两组治疗前后的血脂水平、临床疗效、中医证候疗效及治疗期间不良反应发生情况。结果 治疗前,两组血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、脂蛋白(a)、载脂蛋白B(ApoB)、载脂蛋白A1水平差异均无统计学意义(均P>0.05)。治疗8周后,两组血清TC、TG、LDL-C、ApoB水平均下降,血清HDL-C水平均升高(均P<0.05);观察组血清TC、TG、LDL-C水平均低于对照组,血清HDL-C水平高于对照组(均P<0.05)。两组临床总有效率差异无统计学意义(P>0.05)。观察组中医证候总有效率高于对照组(94.12%比78.43%,P<0.05),治疗期间不良反应发生率低于对照组(3.92%比15.69%,P<0.05)。结论 大柴胡汤加味方可改善高脂血症(痰瘀内阻证)患者的血脂水平及中医证候,且安全性较好。

Objective To evaluate the clinical efficacy and safety of modified Da Chaihu Tang (Modified Major Bupleurum Decoction) in the treatment of hyperlipidemia (syndrome of phlegm and blood stasis obstructing the interior). Methods A total of 102 patients with hyperlipidemia (syndrome of phlegm and blood stasis obstructing the interior) who visited Dazhigu Street Community Health Service Center, Hedong District, Tianjin, from February 2023 to October 2024 were enrolled and assigned to an observation group and a control group using a random number table, with 51 patients in each group. Both groups received lifestyle interventions, the control group received oral simvastatin (once daily, 20 mg per dose), and the observation group received modified Da Chaihu Tang (1 dose daily, taken orally in 2 divided doses). Both groups were treated continuously for 8 weeks. Lipid levels before and after treatment, clinical efficacy, traditional Chinese medicine (TCM) syndrome efficacy, and adverse reactions during treatment were compared between the two groups. Results Before treatment, no significant between-group differences were found in serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), lipoprotein (a), apolipoprotein B (ApoB), or apolipoprotein A1 levels (all P>0.05). After 8 weeks of treatment, serum TC, TG, LDL-C, and ApoB levels decreased in both groups, and serum HDL-C levels increased in both groups (all P<0.05). Serum TC, TG, and LDL-C levels in the observation group were lower than those in the control group, and serum HDL-C levels were higher than those in the control group (all P<0.05). No significant between-group difference was observed in the overall clinical response rate (P>0.05). The overall response rate of TCM syndromes in the observation group was higher than that in the control group (94.12% vs. 78.43%, P<0.05), and the incidence of adverse reactions during treatment was lower than that in the control group (3.92% vs. 15.69%, P<0.05). Conclusion Modified Da Chaihu Tang can improve lipid levels and TCM syndromes in patients with hyperlipidemia (syndrome of phlegm and blood stasis obstructing the interior), with a favorable safety profile.

    无

7

浏览量

0

下载量

0

CSCD

工具集